Peptide clinics: 12 questions to ask before you pay
Last updated: November 4, 2026 · 7 min read · By the Grey Peptides Editorial Board
- A clinic's answers to a few plain questions tell you more than its marketing: who prescribes, which pharmacy makes the product, whether the substance can legally be compounded, and how it was tested.
- Compounded drugs are not FDA-approved. A state-licensed 503A pharmacy is overseen day to day by its state board of pharmacy; a 503B outsourcing facility registers with FDA, is inspected by FDA on a risk-based schedule, and its drugs are subject to current good manufacturing practice 3.
- Some popular peptides have no legal compounding route at all. As of October 27, 2026, BPC-157 sits in none of FDA's interim categories and is not on the 503A list 5 7.
- The biggest red flags are a product labelled for research use only, a claim that something is 'FDA registered' presented as if it meant approved, and promises of guaranteed results.
Why ask at all
The questions below help tell a careful clinic from a risky one, and each answer can be checked against an official source. We name no clinics, because the point is to let you judge any of them.
Questions about who is treating you
1. Who will prescribe, and are they licensed where you live?
Ask for the prescriber's name and the state where they are licensed. Medical licences are issued by state boards, and the best place to start is your state medical board's licence lookup; DocInfo, a free search run by the Federation of State Medical Boards, covers disciplinary history across every state 12. A clinic that will not tell you who signs your prescription is a clinic to leave.
2. Will a clinician evaluate you before prescribing?
A prescription should follow an assessment of your history, your other medicines and your goals, not a checkout page. Ask what that assessment involves, whether it includes blood tests, and who reviews the results.
Questions about what you are getting
3. Is it an approved drug, a compounded drug or a research chemical?
These are three different things. Approved drugs, such as semaglutide High sold as Wegovy, went through FDA review for a specific use. Compounded drugs are made by a pharmacy for a patient, and FDA says plainly that they are not FDA-approved 3. Products labelled research use only are labelled as not for human use, whatever a seller implies.
4. Which pharmacy makes it, and is it a 503A pharmacy or a 503B outsourcing facility?
The answer tells you who checks the pharmacy. Under section 503A, a licensed pharmacist in a state-licensed pharmacy compounds for individual patients, and state boards of pharmacy "have primary responsibility for the day-to-day oversight" 3. A 503B outsourcing facility registers with FDA, is "inspected by FDA according to a risk-based schedule", and its drugs are subject to current good manufacturing practice requirements (FDA's Q&A, content current as of September 16, 2025) 3. FDA publishes the list of registered outsourcing facilities, updated as of October 23, 2026, and a facility drops off the list unless it re-registers and pays its fee between October 1 and December 31 each year 4. Ask for the pharmacy's name and check it.
5. Can this substance legally be compounded?
Not every peptide can. A 503A pharmacy may compound from bulk ingredients only within the conditions the law sets, and FDA sorts nominated substances into interim categories 5. BPC-157 Low is the best-known example of a gap: FDA's page of substances that may present significant safety risks (content current as of April 22, 2026) lists it under nominations withdrawn, with no date, and cites possible immune reactions and product-quality concerns 6; as of October 27, 2026 it sits in none of the categories on FDA's list, last updated May 14, 2026, and is not among the six substances on the 503A bulks list in FDA's regulation 5 7. Our guide to FDA's categories explains the system.
On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157, TB-500, MOTS-c, KPV, semax and epitalon under the forms, routes and conditions in its Appendix B 8. The policy is non-binding, labelled a draft and open to revision; FDA has not added any of them to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).
6. How was it tested, and can you see the results?
Drugs from outsourcing facilities are subject to current good manufacturing practice requirements 3. For any product, ask for its certificate of analysis: what was tested (identity, strength, sterility, endotoxin), by whom and when, and for which batch. A clinic that cannot produce one cannot tell you what is in the vial.
Questions about whether it works and what could go wrong
7. What is the evidence for your goal?
Ask what studies support the treatment for what you want it to do, and whether they were in people. The Federal Trade Commission holds health claims to a standard of competent and reliable scientific evidence, which for health benefits generally means randomized, controlled human trials 9. For BPC-157, FDA's 2026 review of the literature found five clinical studies, only one of them randomised and placebo-controlled, known from a meeting abstract 10; our fact-check of popular claims shows how far apart the two can be.
8. What monitoring will you get?
Ask which blood tests are done before you start and how often afterwards, who reads them, and what result would make them stop or change the treatment. Monitoring that exists only on a brochure is not monitoring.
9. What are the risks, and will you sign consent that names them?
Informed consent should name the known risks of the specific product, the unknowns, and the alternatives, including approved drugs. For unapproved peptides the unknowns are large: FDA's stated concerns about BPC-157, for example, are possible immune reactions and difficulties with impurities and with characterising the active ingredient 6.
10. What will it cost in total?
Ask for the full price: consultation, lab tests, follow-up visits, the product and supplies, and whether the price changes with the dose. Our guide to what peptide therapy costs in 2026 sets out the published prices for approved drugs.
11. Who do you call about side effects, and will they be reported?
Ask who answers if something goes wrong at night or at the weekend. Serious problems with medicines and other FDA-regulated products can be reported through MedWatch, which FDA describes as its safety reporting program "for health professionals, patients and consumers" (content current as of October 21, 2026) 11; a careful clinic will tell you how it reports them.
12. Are you an athlete who is tested?
If you compete under anti-doping rules, ask before anything else. The World Anti-Doping Agency's 2026 and 2027 lists name BPC-157 among the non-approved substances prohibited at all times, and its rules cover many growth-hormone-related peptides as well 12. A clinic's view of a peptide's safety does not change its status in sport.
Red flags
Some answers should end the conversation. A product labelled for research use only, offered for injection. A claim that something is "FDA registered" presented as if it meant approved: registration applies to facilities such as outsourcing facilities 4, while compounded drugs themselves are not FDA-approved 3. Guaranteed results, or claims with no human studies behind them 9. No named prescriber, no pharmacy name, no certificate of analysis. And pressure to buy a long package before you have been assessed.
Frequently asked questions
How do I check a peptide clinic's prescriber?
Ask for the prescriber's name and licensing state, then check your state medical board's licence lookup. DocInfo, a free search run by the Federation of State Medical Boards, covers disciplinary history across every state.
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
A 503A pharmacy is state-licensed and overseen day to day by its state board of pharmacy. A 503B outsourcing facility registers with FDA, is inspected by FDA on a risk-based schedule and its drugs are subject to current good manufacturing practice. FDA publishes the list of registered facilities.
Are compounded peptides FDA-approved?
No. FDA states that compounded drugs are not FDA-approved. Registration of an outsourcing facility is not approval of the drugs it makes.
Can a clinic legally prescribe compounded BPC-157?
As of October 27, 2026, BPC-157 is in none of FDA's interim categories and not on the 503A bulks list, so it has no recognised route to legal compounding by a 503A pharmacy.
Where can I report a side effect from a peptide?
Through FDA's MedWatch program, which accepts reports from patients and consumers as well as health professionals.
Related on Grey Peptides
- What peptide therapy really costs in 2026
- FDA's Category 1 and 2 explained
- What research use only really means
- Podcast peptide claims, fact-checked
Sources
- Ornstein, C., Waldman, A. and Ojiaku, P. Your Doctor Might Have a Disciplinary Record. Here's How to Find Out. ProPublica (journalism), January 8, 2015, updated December 11, 2019: state licence lookups as the place to start; DocInfo. Read October 2, re-read October 27, 2026. Cited without a link.
- Federation of State Medical Boards. News release describing DocInfo.org as a free online resource on physician licensure and discipline, August 19, 2015 (via Newswise). Read October 2, re-read October 27, 2026. Cited without a link.
- US Food and Drug Administration. Compounding and the FDA: Questions and Answers, content current as of September 16, 2025; read October 2, re-read October 27, 2026. FDA
- US Food and Drug Administration. Registered Outsourcing Facilities, content current as of October 23, 2026 (list updated as of October 23, 2026); read October 27, 2026. FDA
- US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list), updated May 14, 2026; read October 2 and October 27, 2026.
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (fda.gov); read October 2, 2026; re-read October 27, 2026, twice (content current as of April 22, 2026): BPC-157 listed under 'Bulk drug substances nominated but withdrawn', with no date and no category.
- 21 CFR 216.23, bulk drug substances that can be used to compound under section 503A: six substances listed, none a peptide. eCFR text as of October 22, 2026, read October 27, 2026. Cited without a link.
- US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
- Federal Trade Commission. Health Products Compliance Guidance, December 20, 2022 (ftc.gov): health benefit claims need competent and reliable scientific evidence, generally randomized, controlled human clinical testing. Read October 2, re-read October 27, 2026. Cited without a link.
- US Food and Drug Administration. BPC-157 briefing document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (dated May 11, 2026): five clinical studies, one randomised placebo-controlled study presented as a meeting abstract. Read October 27, 2026. FDA
- US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program, content current as of October 21, 2026; read October 2, re-read October 27, 2026. FDA
- World Anti-Doping Agency. The 2026 and 2027 Prohibited Lists: S0 (non-approved substances), which names BPC-157, and S2.2.4 (growth hormone releasing factors). Read October 2, re-read October 27, 2026. WADA 2027 List
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead